Advicenne Has Submitted to US FDA the Registration Application for Sibnayal® in dRTA Treatment

Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases ...

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a ...

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million ---- December 20, 2025 PDUFA goal date ...

Rise Health Nano Optics Granted Third U.S. Patent for Breakthrough Nano-Optic Technology Advancing Preventative Vision Care

Rise Health Nano Optics Inc. ("Rise" or the "Company"), a health technology innovator specializing in nano-optic solutions ...
Le Lézard

Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance

Pfizer Inc. reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY ...